Project/Area Number |
04670902
|
Research Category |
Grant-in-Aid for General Scientific Research (C)
|
Allocation Type | Single-year Grants |
Research Field |
Orthopaedic surgery
|
Research Institution | OSAKA CITY UNIVERSITY |
Principal Investigator |
ISHIDA Toshitake Department of Orthopedics Medical School, OSKA CITY UNIVERSITY Associate Professor, 医学部, 助教授 (30046908)
|
Co-Investigator(Kenkyū-buntansha) |
TAKAMI Masatsugu Department of Orthopedics Medical School, OSKA CITY UNIVERSITY Lecturer, 医学部, 講師 (50188083)
黒田 裕子 大阪市立大学, 医学部, 研究医
|
Project Period (FY) |
1992 – 1994
|
Project Status |
Completed (Fiscal Year 1994)
|
Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1994: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1993: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1992: ¥700,000 (Direct Cost: ¥700,000)
|
Keywords | hollow fiber bioreactor / LAK cell |
Research Abstract |
Osteosarcoma patients who had failed standard therapy and had multiple metastatic disease seems to be intractable. Rosenberg et al, have recently reported that combined therapy with LAK cells and IL-2 was capable of causing the regression of established metastatic cancer. In prior murine model, it is said that the therapeutic effect was directly related to the number of LAK cells and amount of IL-2 adminstered. In order to apply this adoptive immunotherapy to the advanced osteosarcoma patients, at first we have studied methods for in vitro expansion of LAK cells effective in immunotherapy. A hollow fiber biorcactor system (Cellmax 100) was used and its efficacy was investigated in LAK cell proliferatioin, PBL obtained from 20 ml of peripheral blood were cultured in an anti-CD 3 antibody coated flask for 7 days. About 2-4 *10 cells were harvested. These LAK cells were transfered to the hollow fiber bioreacter and cultured for further 2 weeks. The number of LAK cells did not increase in hollow fiber bioreactor. In their surface marker. Leu 4a (CD3+) cells were 98-99% at both 1 and 2 weeks. Leu 2a (CD8+) cells were 55% at 1 week, 74% at 2 weeks. Leu 3a (CD4+) cells were 48% at 1 week. 25% at 2 weeks. The ration of CD4/8 was decreased with time. We could not apply this adoptive immunotherapy to advanced osteosarcoma patients.
|